🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 57 of 857 · Phase 3 first, then by program name

  1. Dupilumab SAR231893

    Regeneron UK Limited

    Chronic Rhinosinusitis Without Nasal Polyps

    phase 3 small molecule completed

    1 trial

  2. Dupilumab SAR231893

    Regeneron UK Limited

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule completed

    2 trials

  3. Dupilumab SAR231893

    Regeneron UK Limited

    Chronic Spontaneous Urticaria

    phase 3 small molecule completed

    1 trial

  4. Dupilumab SAR231893

    Regeneron UK Limited

    Asthma

    phase 3 small molecule completed

    1 trial

  5. Dupilumab SAR231893

    Regeneron UK Limited

    Neurodermatitis

    phase 3 small molecule completed

    2 trials

  6. Dupilumab SAR231893

    Regeneron UK Limited

    Allergic Fungal Rhinosinusitis

    phase 3 small molecule completed

    1 trial

  7. Dupilumab SAR231893 (REGN668)

    Regeneron UK Limited

    Asthma

    phase 3 small molecule completed

    2 trials

  8. Dupilumab SAR231893 (REGN668)

    Regeneron UK Limited

    Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)

    phase 3 small molecule completed

    2 trials

  9. Dupilumab, Matched placebo for test product

    Sanofi-aventis Healthcare Pty Ltd

    Neurodermatitis

    phase 3 small molecule active

    1 trial

  10. Dupilumab, Matched placebo for test product

    Sanofi-aventis Healthcare Pty Ltd

    Neurodermatitis

    phase 3 small molecule active

    1 trial

  11. Dupixent 200 mg solution for injection in pre-filled syringe, Dupixent 300 mg solution for injection in pre-filled pen, Dupixent 300 mg solution for injection in pre-filled syringe, Dupixent 200 mg solution for injection in pre-filled pen

    Lacuna Pharma Pty Ltd

    Atopic Dermatitis

    phase 3 small molecule active

    1 trial

  12. Durvalumab

    Arcus Biosciences

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  13. Durvalumab

    AstraZeneca

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    2 trials

  14. Durvalumab

    AstraZeneca

    Muscle Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  15. Durvalumab

    AstraZeneca

    Locally Advanced Cervical Cancer

    phase 3 mab completed

    1 trial

  16. Durvalumab

    AstraZeneca

    Non Small Cell Lung Cancer NSCLC

    phase 3 small molecule active

    1 trial

  17. Durvalumab

    AstraZeneca

    Hepatocellular Carcinoma

    phase 3 small molecule active

    2 trials

  18. Durvalumab

    AstraZeneca

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule active

    1 trial

  19. Durvalumab

    AstraZeneca

    Cancer

    phase 3 small molecule active

    1 trial

  20. Durvalumab

    AstraZeneca

    Advanced Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial

  21. Durvalumab + SoC chemotherapy

    AstraZeneca

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule completed

    1 trial

  22. Duvakitug

    Teva Pharma GmbH

    Ulcerative Colitis

    phase 3 small molecule active

    2 trials

  23. Duvakitug

    Teva Pharma GmbH

    Crohn's Disease

    phase 3 small molecule active

    2 trials

  24. Duvakitug, Matched placebo for test product

    Sanofi-aventis Healthcare Pty Ltd

    Immune system diseases

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources